Skip to main content

Starting on CRYSVITA may
help manage your TIO

Actor portrayal

Talk to your doctor about CRYSVITA, a treatment proven to help with:

Increasing and maintaining
phosphorus levels in the blood

Helping to heal osteomalacia

(weak or softened mature bone)

Talk to your doctor about dosing for CRYSVITA

Your doctor may discuss the following:

When starting CRYSVITA, the recommended dose is once every 4 weeks for adults and once every 2 weeks for children
The dosage (the amount of CRYSVITA you take) is based on body weight and will be determined by your doctor. In some cases, this may require more than 1 injection
After initial treatment, your doctor may have to adjust your dose

Discontinue oral phosphate and/or active vitamin D analogs (eg, calcitriol, paricalcitol, doxercalciferol, calcifediol) 1 week prior to initiation of treatment.

If you miss a dose, be sure to receive your next CRYSVITA dose as soon as possible. To avoid missed doses, CRYSVITA may be given up to 3 days before or after the scheduled treatment date.

CRYSVITA is given as an injection under the skin by a healthcare provider

You will receive an injection in 1 of 4 places, to be rotated with each injection:

Upper arm
Upper thigh
Buttocks
Stomach

Injection sites on upper arm, stomach, upper leg, and buttocks

If the tumor can't be removed, CRYSVITA may help to treat your TIO.

Have questions about access and reimbursement?

Connect with a Kyowa Kirin Cares case manager who can help you understand your financial options.

What’s next when you have a CRYSVITA prescription

Receiving and storing CRYSVITA

What to do when CRYSVITA is delivered

Find helpful CRYSVITA resources

Tools that can support your CRYSVITA journey

CRYSVITA frequently asked questions

Get answers to your CRYSVITA questions

Stay informed

Learn more about CRYSVITA, connect with a support community, and receive invites to important educational events.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 2 years of age and older with fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumor-induced osteomalacia (TIO) when the tumor cannot be located or removed.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 2 years of age and older with fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumor-induced osteomalacia (TIO) when the tumor cannot be located or removed.

Important Safety Information

You should not take CRYSVITA if:

You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).

Your phosphorus levels from a blood sample are within or above the normal range for age.
You have kidney problems.

What is the most important information you should know about CRYSVITA?

Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA.
High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels.
Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma).
If you are taking CRYSVITA for TIO, your doctor will have you stop your CRYSVITA treatment temporarily if you are undergoing treatment for your tumor (e.g., surgical removal of the tumor or radiation therapy).

What are the possible side effects of CRYSVITA?

Adverse reactions that were seen in adults with TIO are:
- Tooth abscess
- Muscle spasms
- Dizziness
- Constipation
- Injection site reaction
- Rash
- Headache

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

An allergic reaction such as rash or hives
A rash, swelling, bruising, or other reaction at the injection site
New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 2 years of age and older with fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumor-induced osteomalacia (TIO) when the tumor cannot be located or removed.

Important Safety Information

You should not take CRYSVITA if:

You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
Your phosphorus levels from a blood sample are within or above the normal range for age.
You have kidney problems.

What is the most important information you should know about CRYSVITA?

Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA.
High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels.
Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma).
If you are taking CRYSVITA for TIO, your doctor will have you stop your CRYSVITA treatment temporarily if you are undergoing treatment for your tumor (e.g., surgical removal of the tumor or radiation therapy).

What are the possible side effects of CRYSVITA?

Adverse reactions that were seen in adults with TIO are:
- Tooth abscess
- Muscle spasms
- Dizziness
- Constipation
- Injection site reaction
- Rash
- Headache

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

An allergic reaction such as rash or hives
A rash, swelling, bruising, or other reaction at the injection site
New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information.